VIO Skin
Overview
Enspectra Health is leading the digital era in dermatology with its first-in-class cross-modal technology. This innovative handheld technology instantly generates high-resolution digital images of live cells without the need for an incision, providing valuable AI-powered insights for all aspects of skin health.
The VIO System is a revolutionary skin imaging system that combines novel multiphoton laser scanning with reflectance confocal microscopy to deliver actionable cellular information noninvasively in real time. Enspectra Health’s mission is to transform how skin is evaluated and managed by leveraging groundbreaking imaging and machine learning technology, arming dermatologists with the data they need, at the point of care in real time, to provide advanced patient-centric care.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered insights
- First-in-class cross-modal technology
- Handheld and portable device
- Instantly generates high-resolution digital images of live cells
- Non-invasive (virtual biopsy, no incision)
- Combines multiphoton laser scanning with reflectance confocal microscopy
- Delivers actionable cellular information in real-time
- Digitizes pathology directly from a patient's skin
- Provides cross-sectional, histology-like images of skin
- Aids in clinical decision-making
Use Cases
- Evaluating skin lesions non-invasively
- Assessing lesions suspicious of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in high-risk populations
- Tracking changes in skin tissue over time (e.g., aging skin, sun damage, treatment efficacy)
- Minimizing unnecessary biopsies and facilitating earlier disease diagnosis
- Evaluating general skin health and photoaging
- Assessing efficacy of topical drugs in pigmentation disorders, rashes, eczema, and similar conditions
What Physicians Need to Know
Consider VIO Skin for high-risk patients requiring frequent monitoring or when a non-invasive, real-time assessment of suspicious lesions (BCC/SCC) is beneficial to reduce unnecessary biopsies. Its ability to provide cellular-level insights at the point of care can significantly streamline diagnostic workflows and inform immediate clinical decisions. The portability makes it adaptable to various clinical settings. Keep an eye on its expanded indications and AI/ML algorithm advancements for broader dermatological applications.
The primary integration highlighted is the combination of the VIO imaging technology with its proprietary VIO.ai NMSC software for computer-aided diagnosis. While the device is portable and designed for point-of-care use, specific details regarding integration with existing electronic health record (EHR) systems or other hospital information systems were not explicitly mentioned in the available information.
Details
| Category | Dermatology AI |
| Pricing | Contact for pricing |
| Deployment | On-premise (device-based) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The VIO System received FDA 510(k) clearance in January 2024, marking it as the first multiphoton imaging modality cleared by the FDA. The VIO Skin Platform also holds FDA Breakthrough Device Designation for evaluating lesions suspicious of basal cell and squamous cell carcinoma in high-risk populations. |
| Integrations | |
| EHR | Not specified |
| Specialties | Dermatology, Pathology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate VIO Skin
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for VIO Skin.
Our Visia Skin Analysis! The Ultimate way to discover your skin's unique needs
Frequently Asked Questions
Investors who backed VIO Skin
Funded through the company that built this tool.
